UNITED THERAPEUTICS Corp

Form 4 May 01, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL OMB

Number:

3235-0287

Expires:

January 31, 2005

0.5

response...

Estimated average burden hours per

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * ROTHBLATT MARTINE A

2. Issuer Name and Ticker or Trading Symbol

Issuer

5. Relationship of Reporting Person(s) to

UNITED THERAPEUTICS Corp [UTHR]

(Check all applicable)

CEO

below)

(Last) (First)

05/01/2014

(Month/Day/Year)

Filed(Month/Day/Year)

3. Date of Earliest Transaction

_X__ Director X_ Officer (give title below)

10% Owner Other (specify

C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING

STREET

(City)

4. If Amendment, Date Original

Applicable Line)

(Street)

(Middle)

(Zip)

X Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

Person

SILVER SPRING, MD 20910

(State)

Security (Instr. 3) (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Disposed of (D) (Dough any (Month/Day/Year)) Securities (Instr. 3, 4 and 5) Ownership Beneficially (Instr. 4) Form: Beneficially (Instr. 4) Securities (Instr. 3, 4 and 5) Owned Poliowing Reported (Instr. 4) Form: Beneficially (Instr. 4) Beneficially (Instr. 4) Owned Poliowing (Instr. 4) Securities (Instr. 3, 4 and 5) Owned Poliowing Reported (Instr. 3, 4 and 5) Securities (Instr. 3, 4 and 5) Owned Poliowing Reported (Instr. 3, 4 and 5) Securities (Instr. 4) Owned Poliowing (Instr. 4) Securities (Instr. 3, 4 and 5) Owned Poliowing Reported (Instr. 3, 4 and 5) Securities (Instr. 3, 4 and 5) Owned Poliowing Reported (Instr. 3, 4 and 5) Securities (Instr. 4) Owned Poliowing (Instr. 4) Securities (Instr. 4) Owned Poliowing Reported (Instr. 3, 4 and 5) Securities (Instr. 4) Owned Poliowing Reported (Instr. 3, 4 and 5) Securities (Instr. 4) Owned Poliowing Reported (Instr. 3, 4 and 5) Securities (Instr. 4) Owned Poliowing Reported (Instr. 4) Owned Poliowing Reported (Instr. 4) Securities (Instr. 4) Owned Poliowing Reported (Instr. 4) Securities (Instr. 4) Owned Po	(City)	(State)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
Common Stock 05/01/2014 Code V Amount (D) Price (Instr. 3 and 4) Common Stock 05/01/2014 3,833 A \$ 34.56 (2) 3,973 D Common Stock 05/01/2014 \$ 3,833 D \$ 101.587 (3) 140 D Common Stock 05/01/2014 \$ 3,233 A \$ 30.75 (2) 5,373 D Common Stock 05/01/2014 \$ 99.21 (2) 5,173 D	Security		Execution Date, if any	Transactio Code	onor Disposed of (D) (Instr. 3, 4 and 5) (A)			Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock $05/01/2014$ $M(\underline{1})$ $3,833$ A $(\underline{2})$ $3,973$ D Common Stock $05/01/2014$ $S(\underline{1})$ $3,833$ D $S(\underline{1})$				Code V	Amount		Price	(Instr. 3 and 4)		
Stock $05/01/2014$ Set of stock $3,833$ D (3) (3) (3) (3) (4) 140 D (3) (3) (3) (4) (4) (4) (5) (4) (4) (5) (4) (4) (5) (4) (4) (5) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4		05/01/2014		M(1)	3,833	A		3,973	D	
Stock 05/01/2014 M(1) 5,233 A (2) 5,373 D Common Stock 05/01/2014 S(1) 200 D \$99.21 5,173 D		05/01/2014		S(1)	3,833	D		140	D	
Stock $05/01/2014$ $S(1)$ 200 D (4) (4) $(5,1/3)$ D		05/01/2014		M <u>(1)</u>	5,233	A		5,373	D	
05/01/2014 S(1) 700 D 4.473 D		05/01/2014		S(1)	200	D		5,173	D	
03/01/2014 3 <u>~</u> /00 D 4,4/3 D		05/01/2014		S(1)	700	D		4,473	D	

Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

Common Stock					\$ 100.6057 (5)			
Common Stock	05/01/2014	S <u>(1)</u>	2,233	D	\$ 102.006 (6)	2,240	D	
Common Stock	05/01/2014	S <u>(1)</u>	1,900	D	\$ 102.7005 <u>(7)</u>	340	D	
Common Stock	05/01/2014	S(1)	200	D	\$ 103.415 (8)	140	D	
Common Stock						166	I	By Spouse
Common Stock						533,094.05	I	By Trusts

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number ction Derivative Securities 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	\$ 34.56 (2)	05/01/2014		M(1)		3,833	12/30/2005	12/30/2015	Common Stock	3,833
Stock Options	\$ 30.75 (2)	05/01/2014		M <u>(1)</u>		5,233	12/26/2009	12/31/2017	Common Stock	5,233

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Reporting Owners 2

Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

X

ROTHBLATT MARTINE A
C/O UNITED THERAPEUTICS CORPORATION
1040 SPRING STREET
SILVER SPRING, MD 20910

CEO

Signatures

/s/ John S. Hess, Jr. under Power of Attorney

05/01/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- (2) Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
- This transaction was executed in multiple trades at prices ranging from \$101.4901 to \$101.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$99.07 to \$99.35. The price reported above reflects the weighted (4) average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$100.21 to \$101.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$101.25 to \$102.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$102.26 to \$103.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$103.37 to \$103.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3